vs
Enact Holdings, Inc.（ACT）与Embecta Corp.（EMBC）财务数据对比。点击上方公司名可切换其他公司
Enact Holdings, Inc.的季度营收约是Embecta Corp.的1.2倍（$312.1M vs $261.2M），Enact Holdings, Inc.净利率更高（53.8% vs 16.9%，领先37.0%），Enact Holdings, Inc.同比增速更快（1.7% vs -0.3%），过去两年Enact Holdings, Inc.的营收复合增速更高（2.2% vs -4.6%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
ACT vs EMBC — 直观对比
营收规模更大
ACT
是对方的1.2倍
$261.2M
营收增速更快
ACT
高出2.0%
-0.3%
净利率更高
ACT
高出37.0%
16.9%
两年增速更快
ACT
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $312.1M | $261.2M |
| 净利润 | $168.0M | $44.1M |
| 毛利率 | — | 61.9% |
| 营业利润率 | — | 31.9% |
| 净利率 | 53.8% | 16.9% |
| 营收同比 | 1.7% | -0.3% |
| 净利润同比 | 1.2% | — |
| 每股收益（稀释后） | $1.18 | $0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTEMBC
| Q1 26 | $312.1M | — | ||
| Q4 25 | $312.7M | $261.2M | ||
| Q3 25 | $311.5M | $264.0M | ||
| Q2 25 | $304.9M | $295.5M | ||
| Q1 25 | $306.8M | $259.0M | ||
| Q4 24 | $301.8M | $261.9M | ||
| Q3 24 | $309.6M | $286.1M | ||
| Q2 24 | $298.8M | $272.5M |
净利润ACTEMBC
| Q1 26 | $168.0M | — | ||
| Q4 25 | — | $44.1M | ||
| Q3 25 | — | $26.4M | ||
| Q2 25 | — | $45.5M | ||
| Q1 25 | — | $23.5M | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $14.6M | ||
| Q2 24 | — | $14.7M |
毛利率ACTEMBC
| Q1 26 | — | — | ||
| Q4 25 | — | 61.9% | ||
| Q3 25 | — | 60.0% | ||
| Q2 25 | — | 66.7% | ||
| Q1 25 | — | 63.4% | ||
| Q4 24 | — | 60.0% | ||
| Q3 24 | — | 60.7% | ||
| Q2 24 | — | 69.8% |
营业利润率ACTEMBC
| Q1 26 | — | — | ||
| Q4 25 | 71.3% | 31.9% | ||
| Q3 25 | 67.4% | 21.4% | ||
| Q2 25 | 70.4% | 31.8% | ||
| Q1 25 | 68.9% | 24.3% | ||
| Q4 24 | 68.9% | 11.0% | ||
| Q3 24 | 74.1% | 9.2% | ||
| Q2 24 | 78.6% | 20.5% |
净利率ACTEMBC
| Q1 26 | 53.8% | — | ||
| Q4 25 | — | 16.9% | ||
| Q3 25 | — | 10.0% | ||
| Q2 25 | — | 15.4% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 5.1% | ||
| Q2 24 | — | 5.4% |
每股收益（稀释后）ACTEMBC
| Q1 26 | $1.18 | — | ||
| Q4 25 | $1.23 | $0.74 | ||
| Q3 25 | $1.10 | $0.44 | ||
| Q2 25 | $1.11 | $0.78 | ||
| Q1 25 | $1.08 | $0.40 | ||
| Q4 24 | $1.05 | $0.00 | ||
| Q3 24 | $1.15 | $0.24 | ||
| Q2 24 | $1.16 | $0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $549.0M | $201.3M |
| 总债务越低越好 | $744.9M | — |
| 股东权益账面价值 | $5.3B | $-613.1M |
| 总资产 | $7.0B | $1.1B |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资ACTEMBC
| Q1 26 | $549.0M | — | ||
| Q4 25 | $582.5M | $201.3M | ||
| Q3 25 | $545.6M | $225.5M | ||
| Q2 25 | $616.0M | $230.6M | ||
| Q1 25 | $639.0M | $209.3M | ||
| Q4 24 | $602.8M | $210.0M | ||
| Q3 24 | $674.9M | $267.5M | ||
| Q2 24 | $711.3M | $275.1M |
总债务ACTEMBC
| Q1 26 | $744.9M | — | ||
| Q4 25 | $744.5M | — | ||
| Q3 25 | $744.1M | $1.4B | ||
| Q2 25 | $743.8M | — | ||
| Q1 25 | $743.4M | — | ||
| Q4 24 | $743.0M | — | ||
| Q3 24 | $742.7M | $1.6B | ||
| Q2 24 | $742.4M | — |
股东权益ACTEMBC
| Q1 26 | $5.3B | — | ||
| Q4 25 | $5.4B | $-613.1M | ||
| Q3 25 | $5.3B | $-650.6M | ||
| Q2 25 | $5.2B | $-669.6M | ||
| Q1 25 | $5.1B | $-736.2M | ||
| Q4 24 | $5.0B | $-768.8M | ||
| Q3 24 | $5.0B | $-738.3M | ||
| Q2 24 | $4.8B | $-763.7M |
总资产ACTEMBC
| Q1 26 | $7.0B | — | ||
| Q4 25 | $6.9B | $1.1B | ||
| Q3 25 | $6.9B | $1.1B | ||
| Q2 25 | $6.8B | $1.2B | ||
| Q1 25 | $6.7B | $1.1B | ||
| Q4 24 | $6.5B | $1.1B | ||
| Q3 24 | $6.6B | $1.3B | ||
| Q2 24 | $6.3B | $1.3B |
负债/权益比ACTEMBC
| Q1 26 | 0.14× | — | ||
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.15× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $17.2M |
| 自由现金流经营现金流 - 资本支出 | — | $16.6M |
| 自由现金流率自由现金流/营收 | — | 6.4% |
| 资本支出强度资本支出/营收 | — | 0.2% |
| 现金转化率经营现金流/净利润 | — | 0.39× |
| 过去12个月自由现金流最近4个季度 | — | $205.8M |
8季度趋势，按日历期对齐
经营现金流ACTEMBC
| Q1 26 | — | — | ||
| Q4 25 | $724.5M | $17.2M | ||
| Q3 25 | $192.0M | $84.0M | ||
| Q2 25 | $119.5M | $81.2M | ||
| Q1 25 | $226.7M | $31.8M | ||
| Q4 24 | $686.3M | $-5.3M | ||
| Q3 24 | $188.1M | $26.6M | ||
| Q2 24 | $144.7M | $-2.1M |
自由现金流ACTEMBC
| Q1 26 | — | — | ||
| Q4 25 | — | $16.6M | ||
| Q3 25 | — | $76.7M | ||
| Q2 25 | — | $80.8M | ||
| Q1 25 | — | $31.7M | ||
| Q4 24 | — | $-6.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-11.8M |
自由现金流率ACTEMBC
| Q1 26 | — | — | ||
| Q4 25 | — | 6.4% | ||
| Q3 25 | — | 29.1% | ||
| Q2 25 | — | 27.3% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | -2.6% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -4.3% |
资本支出强度ACTEMBC
| Q1 26 | — | — | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 3.6% |
现金转化率ACTEMBC
| Q1 26 | — | — | ||
| Q4 25 | — | 0.39× | ||
| Q3 25 | — | 3.18× | ||
| Q2 25 | — | 1.78× | ||
| Q1 25 | — | 1.35× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | -0.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
| Premiums | $242.8M | 78% |
| Other | $69.2M | 22% |
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
